Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor ...

Veru anticipates filing a new IND for sabizabulin to address inflammation in atherosclerotic cardiovascular disease, with Phase 2 studies using coronary CT angiography as the primary endpoint. IND ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

a novel oral selective androgen receptor modulator (SARM), led to a statistically significant reduction in lean mass loss in patients receiving semaglutide (WEGOVY), a GLP-1 receptor agonist, for ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002 ... 2024 (GLOBE NEWSWIRE) -- Veru Inc.

It was dubbed the "King Kong" of weight loss drugs by US expert Dr Julio Rosenstock after its effect size emerged , compared to the "gorilla" of Wegovy. The two biggest selling GLP-1 drugs are ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 million and a GIP-targeting asset intended to induce higher-quality weight ...